Drug
Sorafenib Mfolfox6
Sorafenib Mfolfox6: highest development phase Phase 2, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) NCT00865709 | Phase 2 | Metastatic Colorectal Cancer |
Latest
No recent events.
Follow Sorafenib Mfolfox6 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.